GV-backed solid tumour treatment developer Pact Pharma has completed an oversubscribed $75m series C round led by Vida Ventures.
Pact Pharma, a US-based immuno-oncology drug developer backed by internet and technology conglomerate Alphabet, has closed a $75m series C round led by life science-focused venture capital firm Vida Ventures.
The oversubscribed round also featured several existing shareholders, though their identity was not disclosed. The company has now raised more than $200m altogether.
Founded in 2016, Pact Pharma is working on T-cell therapies to treat solid tumours. The approach relies on predictive algorithms that assess mutations in cancer tissue, with…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
